A phase II study of nilotinib, a novel tyrosine kin ase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy.

被引：1
|
作者：
Giles, Francis
le Coutre, Philipp
Bhalla, Kapil
Rosti, Gianantonio
Ossenkopplele, G. J.
Alimena, Giuliana
Weitzman, Aaron
Rafferty, Teresa
Zheng, Ming
Kantarjian, Hagop
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Campus Virchow Klin, Berlin, Germany
[3] H Lee Moffitt Canc Ctr, Tampa, FL USA
[4] Univ Bologna Policlin, Azienda Osped, Bologna, Italy
[5] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[6] Univ Roma La Sapienza, Azienda Policlin Umberto, Rome, Italy
[7] Novartis Pharmaceut, E Hanover, NJ USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.2170.2170
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2170
引用
收藏
页码：615A / 616A
页数：2
相关论文
共 50 条
  • [11] A phase II study of nilotinib,a noveltyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with philadelphiapositive chronic myelogenous leukemia in accelerated phase
    Le Coutre, P.
    Larson, R.
    Kantarjian, H.
    Gattermann, N.
    Hochhaus, A.
    Haque, A.
    Resta, D.
    Weitzman, A.
    Giles, F.
    O'Brien, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 207 - 208
  • [12] Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP)
    Jabbour, E.
    Hochhaus, A.
    le Coutre, P.
    Rosti, G.
    Bhalla, K. N.
    Haque, A.
    Gallagher, N.
    Giles, F. J.
    Cortes, J. E.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [13] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL)
    Larson, R.
    Ottman, O.
    Kantarjian, H.
    le Coutre, P.
    Baccarani, M.
    Weitzman, A.
    Giles, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [14] NILOTINIB IN IMATINIB-RESISTANT OR -INTOLERANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE (CML-AP): UPDATE OF A PHASE 2 STUDY
    le Coutre, P.
    Giles, F. J.
    Hochhaus, A.
    Apperley, J.
    Ossenkoppele, G.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Cortes, J.
    Kantarjian, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 47 - 47
  • [15] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP).
    Kantarjian, H. M.
    Gattermann, N.
    O'Brien, S. G.
    Bhalla, K.
    Hochhaus, A.
    Cervantes, F.
    Alland, L.
    Ottmann, O.
    Giles, F.
    Le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 345S - 345S
  • [16] MINIMAL CROSS-INTOLERANCE BETWEEN NILOTINIB AND IMATINIB IN PATIENTS WITH IMATINIB-INTOLERANT CHRONIC MYELOGENOUS LEUKAEMIA (CML) IN CHRONIC PHASE (CP) OR ACCELERATED PHASE (AP)
    Hochhaus, A.
    Kantarjian, H. M.
    Baccarani, M.
    Le Coutre, P.
    Haque, A.
    Gallagher, N.
    Cortes, J.
    Giles, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 56 - 57
  • [17] Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)
    Wang, Jianxiang
    Huang, Xiaojun
    Hu, Jianda
    Li, Jianyong
    Jin, Jie
    Meng, Fanyi
    Shen, Zhixiang
    Liu, Ting
    Wu, Depei
    Wang, Jianmin
    LEUKEMIA & LYMPHOMA, 2013, 54 : 3 - +
  • [18] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP).
    Le Coutre, P. D.
    Ottmann, O.
    Gatterman, N.
    Larson, R.
    Rafferty, T.
    Alland, L.
    Tavorath, R.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 344S - 344S
  • [19] Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or chronic phase (CP): Preliminary safety analysis
    Nicolini, Franck
    Alimena, Giuliana
    Al-Ali, Haifa-Kathrin
    Zaritskey, Andrey
    Shen, Zhixiang
    Jootar, Saengsuree
    Smith, Graeme
    Hsu, Yanzhi
    Veronese, Maria Luisa
    Rizzieri, David A.
    BLOOD, 2007, 110 (11) : 870A - 870A
  • [20] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or-intolerant chronic phase and accelerated phase Philadelphia-positive chronic myelogenous leukemia
    Giles, F.
    Le Coutre, P.
    Bhalla, K.
    Rosti, G.
    Ossenkoppele, G.
    Alimena, G.
    Weitzman, A.
    Haque, A.
    Shou, Y.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 206 - 207
12345